Skip to main content
Oncolys BioPharma Inc. logo

Oncolys BioPharma Inc. — Investor Relations & Filings

Ticker · 4588 ISIN · JP3202170001 T Manufacturing
Open in API
Filings indexed 82 across all filing types
Latest filing 2024-08-09 Interim / Quarterly Rep…
Country JP Japan
Listing T 4588

About Oncolys BioPharma Inc.

https://www.oncolys.com/en/

Oncolys BioPharma Inc. is a biopharmaceutical company focused on the research and development of breakthrough therapies and diagnostics for cancer. The company's core technology is oncolytic virotherapy, which utilizes viruses to selectively target and destroy cancer cells. Its development pipeline addresses multiple stages of cancer care, spanning from early detection and prognostic testing to loco-regional and systemic treatments. The company aims to develop innovative and effective drugs to meet the needs of patients and healthcare providers in the field of oncology.

Recent filings

Filing Released Lang Actions
半期報告書－第21期(2024/01/01－2024/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau in Japan. It covers the fiscal period from January 1, 2024, to June 30, 2024. It contains detailed financial statements, management analysis (MDA), and operational updates, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-09 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 98% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and is submitted to the "関東財務局長" (Kanto Local Finance Bureau Director) on June 14, 2024. It details the offering of "新株予約権証券" (Stock Acquisition Rights Certificates) with specific terms, issuance amounts (2,200,000 yen), exercise price adjustments, and subscription periods. This structure, including the filing type, regulatory submission, and detailed terms for issuing new securities, strongly indicates a filing related to capital raising or securities offering. In the provided definitions, "Capital/Financing Update" (CAP) is the most appropriate category for documents detailing the issuance terms of new securities like stock acquisition rights, as opposed to a general regulatory filing (RNS) or a simple announcement (RPA). The document is comprehensive (nearly 40,000 characters), confirming it is the primary filing document, not just an announcement of one.
2024-06-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is extremely short (589 characters) and contains a table structure typical of a formal submission cover page (提出書類: 確認書 - Confirmation Document) filed with a regulatory body (関東財務局長 - Director of the Kanto Local Finance Bureau) under Japanese financial law (金融商品取引法). The core content confirms that the President (浦田泰生) has verified the appropriateness of the 'Quarterly Report' (四半期報告書) for the first quarter (第21期第１四半期) ending March 31, 2024. This document is a confirmation/attestation regarding a financial report, not the report itself. Since it is a formal confirmation document related to a quarterly report, it doesn't fit perfectly into ER (Earnings Release) or IR (Interim Report). However, given its nature as a formal regulatory confirmation/attestation document that is not explicitly defined elsewhere (like DVA, DIRS, etc.), and its brevity suggesting it's an accompanying filing rather than the main report, the most appropriate general category is Regulatory Filings (RNS), as it is a specific regulatory submission confirming compliance related to the quarterly filing cycle.
2024-05-10 Japanese
四半期報告書－第21期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It contains detailed financial statements, management analysis (MDA), and business updates for the first quarter of the 21st fiscal period (Jan 1, 2024, to Mar 31, 2024). Since it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2024
2024-05-10 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director. The content explicitly details the resolutions passed at the '第20回定時株主総会' (20th Annual General Meeting) held on March 28, 2024. Specifically, it lists the election of directors and a provisional auditor, along with the voting results (votes for, against, abstentions) for each resolution. This content directly relates to the outcomes of a shareholder meeting, which aligns perfectly with the definition of AGM Information (AGM-R) or potentially Declaration of Voting Results & Voting Rights Announcements (DVA). Since the document is the official report detailing the results of the Annual General Meeting resolutions, AGM-R is the most precise fit, although DVA is also highly relevant. Given the context of reporting the results of the *Annual* General Meeting, AGM-R is chosen as the primary classification, as it encompasses the meeting's outcome reporting.
2024-04-03 Japanese
有価証券報告書－第20期(2023/01/01－2023/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, business history, and management information for the fiscal year ending December 31, 2023. It is a comprehensive regulatory filing, not an announcement or a summary. FY 2023
2024-03-29 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.